Treatment With Crizotinib Single Patient Expanded Access IND 134375

Jean M. Tersak, M.D.

Status

Conditions: Inflammatory Myofibroblastic Tumour

Treatments: Drug: Crizotinib

Study type: Expanded Access

Funder types: Other; Industry

Identifiers

NCT03085186

PRO17030033

Details and patient eligibility

About

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Sex: Male

Ages: 2 to 2 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour

Exclusion criteria

• Not applicable as Expanded Access only includes one patient